Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis

Leukemia Supplements volume 3, pages S9–S10 (2014)Cite this article

Subjects

The Mixed Lineage Leukemia gene (MLL1, previously termed HRX, ALL-1, MLL) was identified in humans as a gene at the site of common chromosomal translocations in infant leukemia.1 It is now clear that MLL1 represents a family of histone methyltransferases (HMTs) including its closest relative MLL2 and MLL3, MLL4, SETD1A, SETD1B and possibly MLL5.2 Most of these proteins possess histone H3, lysine 4 (H3K4) HMT activity encoded by the SET domain (for Suvar 3–9, Enhancer of Zeste, Trithorax, epigenetic regulators). Studies of the Drosophila homeotic regulator and MLL1 ortholog, Trithorax, established the paradigm for mechanisms by which these proteins function in vivo.3 For example, the fact that Trithorax regulates clustered homeodomain (Hox) genes prompted this line of investigation in the first loss-of-function mouse Mll1 mutants, which were demonstrated to mis-express multiple Hox genes.4, 5, 6 Since the discovery that the SET domain encodes HMT activity,7, 8 great attention has been paid to this particular enzymatic activity in regulating downstream target genes.

To determine the function of MLL1 in hematopoietic stem/progenitor cells (HSPCs), we previously analyzed conditional knockout animals and determined that deletion of Mll1 rapidly reduced HSPCs through proliferation and cell fate defects.9 Using this model system, we identified genes that were deregulated upon Mll1 deletion in the hematopoietic stem cell (HSC)-enriched LSK/CD48neg population. Small-scale chromatin immunoprecipitation experiments identified a series of transcriptional regulators that were direct MLL1 target genes including Mecom, Pbx1 and Prdm16, which are known to control HSC self-renewal and quiescence.10 To determine whether maintenance of these target genes required the HMT activity of MLL1, a mouse strain in which homozygous germline deletion of the SET domain of MLL1 (ΔSET) was used for the analysis of the hematopoietic system.6 Surprisingly, we found that H3K4 methylation at target genes such as Hoxa9, Mecom and Prdm16 was absolutely normal in hematopoietic cells of ΔSET-mutant animals, as was the expression level of these genes. We also found that retroviral MLL-AF9 expression generated leukemia in ΔSET HSPCs that was indistinguishable in latency or phenotype from leukemia generated in wild-type HSPCs. Collectively, none of the known biological functions of MLL1 in the hematopoietic system required the HMT activity. To understand how MLL1 maintains the expression of its target genes, a survey of histone modifications that undergo changes upon deletion of Mll1 was performed. We identified only histone H4 lysine 16 acetylation (H4K16Ac) as immediately corresponding to the decrease in transcriptional initiation upon MLL1 removal from the target gene promoter regions. This modification is performed by the histone acetyl transferase MOF (also called Myst1 or KAT8), previously discovered as part of the MLL1 protein complex.11 Furthermore, inhibition of SIRT1, a deacetylase that removes H4K16Ac, was sufficient to prevent the loss of transcription at MLL1 targets. These observations together with our data from the MLL1▵SET knockout mouse provide a clear but unexpected mechanism for the maintenance of target gene expression by MLL1 in the hematopoietic cells.12 These studies highlight differences between endogenous MLL1 and MLL-fusion oncoprotein gene regulation mechanisms, suggesting that differential targeting in leukemia may be feasible.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Krivtsov AV, Armstrong SA . MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823–833.

    Article  CAS  Google Scholar 

  2. Shilatifard A . The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012; 81: 65–95.

    Article  CAS  Google Scholar 

  3. Schuettengruber B, Martinez AM, Iovino N, Cavalli G . Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol 2011; 12: 799–814.

    Article  CAS  Google Scholar 

  4. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ . Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995; 378: 505–508.

    Article  CAS  Google Scholar 

  5. Ayton P, Sneddon SF, Palmer DB, Rosewell IR, Owen MJ, Young B et al. Truncation of the Mll gene in exon 5 by gene targeting leads to early preimplantation lethality of homozygous embryos. Genesis 2001; 30: 201–212.

    Article  CAS  Google Scholar 

  6. Terranova R, Agherbi H, Boned A, Meresse S, Djabali M . Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci USA 2006; 103: 6629–6634.

    Article  CAS  Google Scholar 

  7. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107–1117.

    Article  CAS  Google Scholar 

  8. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002; 10: 1119–1128.

    Article  CAS  Google Scholar 

  9. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P . Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007; 1: 324–337.

    Article  CAS  Google Scholar 

  10. Artinger EL, Mishra BP, Zaffuto KM, Li BE, Chung EK, Moore AW et al. An MLL-dependent network sustains hematopoiesis. Proc Natl Acad Sci USA 2013; 110: 12000–12005.

    Article  CAS  Google Scholar 

  11. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005; 121: 873–885.

    Article  CAS  Google Scholar 

  12. Mishra BP, Zaffuto KM, Artinger EL, Org T, Mikkola HK, Cheng C et al. The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis. Cell Reports 2014; 22: 1239–1247.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the laboratory members, past and present, for their contributions to this work and acknowledge the funding from the Lady Tata Foundation (BPM) and from the Gabrielle’s Angel Foundation and American Cancer Society (PE). The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital.

Author information

Authors and Affiliations

  1. Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,

    B P Mishra & P Ernst

  2. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,

    P Ernst

  3. Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,

    P Ernst

Authors
  1. B P Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Ernst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Ernst.

Ethics declarations

Competing interests

PE owns stock in Amgen and has received grant support from the National Institutes of Health (NHLBI and OD), American Cancer Society and Alex’s Lemonade Stand Foundation. BPM has received funding from the Lady Tata Memorial Trust and declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mishra, B., Ernst, P. Deconvoluting MLL1-dependent pathways in hematopoiesis and leukemogenesis. Leukemia Suppl 3 (Suppl 1), S9–S10 (2014). https://doi.org/10.1038/leusup.2014.5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leusup.2014.5

Keywords

Search

Advanced search

Quick links